CASE REPORT

Posterior retroperitoneoscopic resection of recurrent nonseminomatomous tumor mass: a case report of the surgical procedure

Çiğdem Öztürk¹, Harald J. Hoekstra¹, Patrick HJ Hemmer¹, Jourik A. Gietema², and Schelto Kruijff¹,*

¹Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, The Netherlands, and ²Department of Medical Oncology, University of Groningen, University Medical Center Groningen, The Netherlands

*Correspondence address. Department of Surgical Oncology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. Tel: +31 (0)50 3612317; E-mail: s.kruijff@umcg.nl

Abstract

Treatment of stage II–IV nonseminomatous testicular germ cell tumors (NSTGCTs) consists of cisplatin-based combination chemotherapy and, when present, resection of residual retroperitoneal tumor mass (RRTM) by conventional laparotomy or laparoscopy. In case of a retroperitoneal recurrence, a second conventional or laparoscopic procedure may be challenging. A case of late relapse after prior conventional resection of a RRTM and tailor-made surgical management with a posterior retroperitoneoscopic resection (PRR) is reported. A posterior retroperitoneoscopic RRTM resection was performed in a 26-year-old male with a history of stage IIC NSTGCT, presenting with a left-sided retroperitoneal relapse, 6 years after initial treatment. Postoperative course was uneventful and at 1-year follow-up the patient had no evidence of disease. Reoperative surgery by a minimal invasive retroperitoneoscopic approach should be considered as an alternative for patients with a recurrent retroperitoneal tumor mass of a NSTGCT.

INTRODUCTION

Cisplatin-based combination chemotherapy followed by complete resection of residual masses is the cornerstone of advanced nonseminomatous testicular germ cell tumor (NSTGCT) treatment (Fig. 1) [1, 2]. In 8% of NSTGCT patients treated by chemotherapy and adjunctive surgery, recurrent disease is encountered [3]. In the case of a growing teratoma, resection is performed, whereas in the case of presumed vital tumor, initial treatment will be chemotherapy followed by resection of residual tumor mass if indicated [4].

Relapses after prior conventional resections of residual retroperitoneal tumor mass (RRTM) are usually located in the retroperitoneum requiring a laparotomy with extensive surgical exploration. In this case report, an alternative surgical approach, the posterior retroperitoneoscopic resection (PRR), is described.

CASE REPORT

A 26-year-old man was first diagnosed in 2008 with a left-sided testicular tumor treated with inguinal orchectomy. Resection specimen showed primarily embryonal cell carcinoma and...
The surgical procedure was performed by two surgical oncologists with experience in performing posterior retroperitoneoscopic adrenalectomy (PRA) [6]. The procedure was performed with the patient in prone position and the surgeon positioned ipsilateral to the tumor and the assistant at the opposite site. The first part of the surgery involved introduction and developing sufficient retroperitoneal space. A first incision was made below the tip of the 12th rib, eventually serving as camera port, and the second port was then placed without camera view on the index finger (Fig. 3). Pneumoperitoneum was created with a high pressure of 25 mm Hg. After having created enough working space, a third 10-mm port was placed. After mobilizing the left kidney from its surroundings and laterally, the tumor mass could be identified. Tumor resection was performed according to the same oncological principles as in conventional resection of RRTM excising only the visible abnormal retroperitoneal tumor mass. Proximal dissection was carefully performed around the left renal artery and vein. The tumor was gently separated off the aorta by blunt and sharp dissection. Finally, the surgical specimen was placed in an endoscopy bag and extracted from the extraperitoneal cavity. The procedure time was 120 minutes. No intraoperative complications occurred. The patient was discharged the next day. Resection specimen showed a R0 resection of a retroperitoneal tumor mass with remnants of mature teratoma. During 12-month follow-up, the patient had no evidence of disease with normal tumor markers and normal imaging (Fig. 4).

**DISCUSSION**

At the UMCG, the current relapse rate in advanced NSTGCT patients treated with cisplatin-based combination chemotherapy and, if indicated, resection residual disease is 18% [7]. Histology shows that teratoma is often present in late relapses and reoperative surgery [7]. Since teratomas are unresponsive to both chemotherapy and radiotherapy, complete resection of all residual tumor masses is an essential part of the combined treatment of NSTGCTs [4]. Since these retroperitoneal relapses tend to be chemoresistant, a selection of patients with anatomically well-defined retroperitoneal disease require reoperative retroperitoneal surgery. Redo surgeries can be technically challenging because of postchemotherapy desmoplastic reaction and anhilated and scarred surgical tissue planes with dense adhesions due to prior surgery [8–10]. Long-term survival varies from 63 to 91.3%; factors such as recurrence histology, possibility of salvage chemotherapy, anatomical site of recurrence and experience of the surgical oncologist can explain this wide variance in survival rates [10]. The literature concerning reoperative retroperitoneal surgery in NSTGCTs is limited.

Majority of retroperitoneal recurrences are located in the para-aortic mostly left-sided and interaortocaval regions, making reoperative retroperitoneal surgery challenging [10]. Patients who are candidates for resection of recurrent disease should first undergo accurate staging with CT abdomen and chest and MRI, or even PET-CT might be required. This way, patients with extra-abdominal and non-retroperitoneal disease that cannot be surgically cured are excluded. The surgical goal should always be a R0 resection meaning to resect all abnormal tissues. Pedrosa et al. declared 27% of NSTGCTs patients with a relapse even unresectable after attempting redo surgery [10].

In the current patient, technical challenges were taken into account upfront. Residual tumor mass was situated at a difficult and challenging retrocrural location. With the experience...
and confidence gained from the PRA, decision was made to perform a PRR instead of a conventional midline laparotomy. Thus, the previous transabdominal surgical route was bypassed, and surgery could be performed partially in a ‘virgin’ territory creating significantly less morbidity.

Today still most of the surgical resections for recurrent NSTGCTs are performed through a conventional midline or transverse exposure. The retroperitoneoscopic technique as used for adrenalectomy might be an alternative option. However, PRR requires a substantial learning time and is technically challenging [6].

CONCLUSION
In reoperative retroperitoneal surgery in NSTGCTs, an alternative surgical strategy such as PRR can avoid the impact of extended conventional surgery or relaparoscopy on the abdominal organs creating less morbidity with respect to bowel and pulmonary functions.

ACKNOWLEDGEMENTS
N/A.

APPROVAL
There is an ethics approval and consent to participate consent for publication of data and material.

COMPETING INTERESTS
All authors have no competing interests.

FUNDING
There is no funding that was used for this report.

AUTHORS’ CONTRIBUTIONS
See specific form also submitted.

CONTRIBUTION AUTHOR(S)
Study concepts: Öztürk C., Hoekstra H.J., Hemmer P.H., Gietema J.A., and Kruijff S. Study design: Öztürk C., Hoekstra H.J., Hemmer
P.H., Gietema J.A., and Kruijff S. Data acquisition: does not apply. Quality control of data and algorithms: does not apply. Data analysis and interpretation: does not apply. Statistical analysis: does not apply. Manuscript preparation: Öztürk C., Hoekstra H.J., Hemmer P.H., Gietema J.A., and Kruijff S. Manuscript editing: Öztürk C., Hoekstra H.J., Hemmer P.H., Gietema J.A., and Kruijff S. Manuscript review: Öztürk C., Hoekstra H.J., Hemmer P.H., Gietema J.A., and Kruijff S.

ETHICAL APPROVAL FOR RESEARCH
Yes.

EXTERNAL FUNDING
No.

SOURCE OF FUNDING
Does not apply.

NAME OF PRINCIPAL INVESTIGATOR
Ozturk (If funded, please include a statement as to the role of the study sponsor at end of manuscript under a heading ‘Role of the Funding Source’).

POSSIBLE CONFLICT OF INTEREST
No.

‘All the authors have made a significant contribution to this manuscript, have seen and approved the final manuscript and have agreed to its submission to the BMC Urology’.

REFERENCES
1. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder PH, Koops HS, et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001;91:1304–15.
2. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003;21:3310–7.
3. Heidenreich P. Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. Ther Adv Urol 2012;4:187–205.
4. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, et al. EAU guidelines on testicular cancer: 2011 update; European Association of Urology. Eur Urol 2011;60:304–19.
5. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594–603.
6. Vrielink OM, Hemmer PH, Kruijff S. Considerations in minimally invasive adrenal surgery: the frontdoor or the backdoor? Minerva Chir 2018;73:93–9.
7. Ozturk C, Been LB, van Ginkel RJ, Gietema JA, Hoekstra HJ. Laparoscopic resection of residual retroperitoneal tumor mass in advanced Nonseminomatous testicular germ cell Tumors; a feasible and safe oncological procedure. Sci Rep 2019;9:15837.
8. Heidenreich A, Ohlmann C, Hegele A, Beyer J. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol 2005;47:64–71.
9. McKiernan JM, Motzer RJ, Bajorin DF, Bacik GJ, Sheinfeld J. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urologia 2003;62:732–6.
10. Pedrosa JA, Masterson TA, Rice KR, Bihrlle R, Beck SD, Foster RS. Reoperative retroperitoneal lymph node dissection for metastatic germ cell tumors: analysis of local recurrence and predictors of survival. J Urol 2014;19:1777–82.